comprehensive -WSS

comprehensive

author：focus 2025-09-27 23:53:10 - browse：1

Two people in protective equipment work in a lab. — JUAN MABROMATA/AFP via Getty Images

Biosimilars are no longer a new and untested class of medicines. Today, they provide critical treatment options across multiple therapeutic areas. Since the Biologics Price Competition and Innovation Act of 2009 created a regulatory pathway for biosimilar medicine review in the U.S., 37 biosimilars have come to market offering the potential to increase patient choice and cost savings. And according to the 2023 analysis from IQVIA, biosimilars are expected to generate $181 billion in savings for the U.S. health care system over the next five years.

This progress is due, in part, to thoughtfully considered, scientifically robust regulatory standards, which have instilled confidence among health care providers and patients while protecting safety. As a former associate director of therapeutic biologics at the Food and Drug Administration, I had the privilege of helping create and lead implementation of the regulatory framework for biosimilars. The FDA took great care to apply appropriate scientific rigor to the development and approval standards. While I have since moved to Amgen, my goals have remained focused on biosimilar product quality and efficacy, patient safety, and prescriber confidence.

More than a decade later, collective efforts by biosimilar manufacturers and the FDA are paying off.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Judge orders hearing on Trump's motion to disqualify Fulton County DA

hotspot

WSS

Biden has enormous polling lead in Democratic primary, despite challenge from RFK Jr.

Even great ERs can’t make up for American health disparities

5 wounded, 2 critically, in Michigan shopping center shooting

Russian and Belarusian players banned from a women's tennis tournament in Prague

HCA says smaller share of spending going to labor

House GOP plan to stem drug shortages differs from Democrats’

focus

comprehensive

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

Biden administration opens offers in Medicare drug price negotiations

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Trump team launching legal defense fund to help pay legal bills

New air purifier tech could be key to improving indoor air quality

General Catalyst, Summa Health deal will turn on physician buy

ChatGPT in medicine: STAT answers readers' burning questions

China demands US invite Hong Kong leader to economic meeting, adding to strains over crackdown

Anesthesiologist group: stop taking Ozempic before surgery

General Catalyst, Summa Health deal will turn on physician buy

focus

Cybersecurity threat forces Lurie Children's to take systems offline

Snowpack in the West is melting rapidly. Where will all that extra water go?

Philippine ferry was overloaded when it flipped over, leaving 27 dead, official says

Young Chinese opt out of the rat race and pressures at home to pursue global nomad lifestyle

Some dementia cases could be undiagnosed liver disease

Adidas to release second batch of Yeezy sneakers after breakup with Ye

hotspot

focus

leisure time

leisure time